Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13232732 | 1.00 | KMT2A (0.36) | KMT2AMEN1ALDH1A1BRD4CREBBP | |
| SCHEMBL15216504 | 0.85 | KMT2A (0.38) | KMT2AMEN1ALDH1A1TDP1THRB | |
| SCHEMBL6449468 | 0.85 | KMT2A (0.38) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL1004336 | 0.85 | KMT2A (0.38) | KMT2AMEN1ALDH1A1TDP1THRB | |
| SCHEMBL13232749 | 0.85 | CA2 (0.40) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL29514984 | 0.85 | KMT2A (0.38) | KMT2AMEN1ALDH1A1TDP1THRB | |
| SCHEMBL6449477 | 0.83 | KMT2A (0.38) | KMT2AMEN1ALDH1A1TDP1TSHR | |
| SCHEMBL2800278 | 0.83 | PSIP1 (0.36) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL13233049 | 0.83 | PSIP1 (0.36) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL13232800 | 0.82 | NR3C2 (0.41) | KMT2AMEN1ALDH1A1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | KMT2A 4071/4885MEN1 4882/4885ALDH1A1 226/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | KMT2A 4071/4885MEN1 4882/4885ALDH1A1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.